Get Full Government Meeting Transcripts, Videos, & Alerts Forever!
Get email alerts on the Diabetes Cgm Insurance Mandate topic
No spam. Unsubscribe anytime.
Committee votes ITL on bill to mandate insurance coverage for continuous glucose monitors
Summary
After extended debate about clinical benefit, cost and federal/state funding implications, the committee voted to recommend “inexpedient to legislate” (ITL) on a bill that would have expanded insurer coverage of continuous glucose monitoring (CGM) devices beyond current medically necessary uses.
A House committee voted to recommend ITL (inexpedient to legislate) on a bill that would have required insurers to cover continuous glucose monitors (CGMs) more broadly, concluding that questions about clinical benefit for non‑insulin patients and potential costs to premiums and the state remained unresolved.
Why it mattered: supporters framed CGMs as a tool that can improve real‑time glucose management and potentially reduce complications; opponents and department analysts said the clinical literature does not consistently show A1C improvement for non‑insulin therapies and that the fiscal impacts — including obligations under the Affordable Care Act — could expose the state to defrayal costs.
Key numbers and claims: a committee member quoted the department’s mandate study estimate that the equipment costs about $1,383 per year and that, assuming a 26 percent take‑up, the per‑member annual impact would be about $48 on an insurer’s risk pool. Committee discussion included alternate, simpler per‑member estimates on the order of a few dollars per month when costs are spread across a full insured population, but members emphasized uncertainty in uptake and clinical effect.
Clinical and legal points: some witnesses urged coverage for type‑1 diabetics and for medically necessary uses; department staff said CGMs are already covered when medically necessary. The department also advised that adding a new benefit in the individual and small‑group market could require the state to defray costs under federal law for Qualified Health Plans.
Committee concerns and outcome: members raised questions about which patient populations would benefit, the prescription requirement for device access and whether the bill would raise premiums for small employers. After debate, the committee took a straw vote recommending ITL; members seeking a different outcome were advised they may pursue amendments or a minority report to pursue floor action.
